The goal of this clinical research study is to find out if rhIL-11（Interleukin 11） may increase the platelet count in Childhood patients with acute lymphocytic leukemia (ALL) who develop low platelet counts while receiving standard CAT（cyclophosphamide+Cytosine arabinoside+mercaptopurine，7d） therapy.
Group A：patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80,000/mL Group B：control group
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL
Beijing Children's Hospital
Beijing, Beijing Municipality, China
Nanjing Children's Hospital
Nanjing, Jiangsu, China
Soochow University Affiliated Children's Hospital
Suzhou, Jiangsu, China
Shanghai Children's Medical Center
Shanghai, Shanghai Municipality, China
platelet infusion
frequency of platelet infusion
Time frame: 14 days
hemorrhagic tendency
conditions of bleeding
Time frame: 14 days
infection
incident of infection during 14d after chemotherapy
Time frame: 14 days
remission rate
remission rate during 14d after chemotherapy
Time frame: 14 days
platelet Count
recovery of peripheral platelet count
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China